Software to track detailed flows from prescriptions to drug usage at the patient level

An article in the New York Times (May 16,2013) describes software that uses insurance records, claims etc to track individual drug prescriptions from doctors to patients to pharmacies, including refills, albeit without patient identifiers. But the data does include details such as income and ethnicity. Pharmaceutical companies claim that this helps them target potential demand sources, offer more efficient alternatives, identify interactions across doctors based on patient and other flows to target market their products etc. But is the data so refined that individual patient histories will now become available to pharmaceutical companies and if so, is there an implied worry ? Will more targeted marketing lower pharmaceutical company costs and thus lower drug costs and help the patient ? More generally, is there a benefit to the supply chain as a whole (costs or efficacy) if detailed usage data becomes available ?

Advertisements

About aviyer2010

Professor
This entry was posted in Operations Management, Service Operations, Supply Chain Issues and tagged , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s